The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An observational/translational study to conduct real-world evidence and develop biomarkers of fruquintinib for patients with metastatic colorectal cancer (mCRC): FruBLOOM trial (JACCRO CC-19).
 
Yu Sunakawa
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Guardant Health; Incyte; Lilly Japan; Merck; MSD K.K; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo; Merck; MSD K.K
Research Funding - Chugai Pharma; Taiho Pharmaceutical
 
Chiaki Inagaki
Stock and Other Ownership Interests - Eisai
Speakers' Bureau - Daiichi Sankyo/UCB Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma; Epochal Precision Anti-Cancer Therapeutics; Ono Pharmaceutical
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly Japan; Merck; Miyarisan pharmaceutical; MSD K.K; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Kota Ouchi
No Relationships to Disclose
 
Toshihiro Kudo
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly Japan; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Daiichi Sankyo
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo/UCB Japan (Inst); Incyte Japan (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
 
Hironaga Satake
Honoraria - Asahi KASEI; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Asahi Kasei (Inst); Daiichi Sankyo (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Tomomi Kashiwada
No Relationships to Disclose
 
Eisuke Inoue
Consulting or Advisory Role - Nippon Tect Systems; Pfizer
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Eisai
 
Ryo Matoba
Leadership - DNA Chip Research
Stock and Other Ownership Interests - DNA Chip Research
 
Wataru Ichikawa
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health; Lilly; Merck; MSD K.K; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst)